

TRANSLATIONAL BREAST CANCER RESEARCH

A JOURNAL FOCUSING ON TRANSLATIONAL RESEARCH IN BREAST CANCER

2023 ANNUAL REPORT

Editorial Office
tbc@amegroups.com

Outline of the Report

1. General Information
2. Editor-in-Chief
3. Geographic Distribution of Editorial Board Members
4. Number of Published Articles in 2023
5. Type of Articles Published in 2023
6. Geographic Distribution of 2023 Corresponding Authors
7. Website Visits in 2023
8. Pageviews in 2023
9. Most Viewed Articles Published in TBCR
10. Reviewer of the Month (2023)
11. Interviews with Outstanding Authors (2023)
12. Cover Image Display
13. Introduction to the Publisher AME

1. General Information



Translational Breast Cancer Research

- Open-access
- Peer-review
- Quarterly publication

- Formally launched in November 2019
- Member of Committee on Publication Ethics (COPE)

TBCR focuses on translational research in breast cancer and contains articles dealing with laboratory investigations as well as clinical studies.

2. Editor-in-Chief




Editor-in-Chief

Prof. Dr. Zefei Jiang, MD
Department of Oncology, The Fifth Medical
Center of Chinese PLA General Hospital,
Beijing, China

More details



3. Geographic Distribution of Editorial Board Members




In 2023, the number of editorial board members amounted to **77** with leading domestic and overseas experts joining us, mainly from China, Italy, USA, Japan, Germany and UK, etc.

A Collage of TBCR Editorial Team Members



Note: Data were collected from January 1, 2023 to December 29, 2023.


4. Number of Published Articles in 2023



As a quarterly publication, TBCR published **4** issues in 2023. Each issue focused on a particular theme, which features a current hot topic in breast cancer research.

Note: Data were collected from January 1, 2023 to December 29, 2023


5. Type of Articles Published in 2023



TBCR published **33** pieces of articles in 2023, among which there are Original Article, Guideline, Case Report, Review Article, Editorial and other types.

Note: Data were collected from January 1, 2023 to December 29, 2023


6. Geographic Distribution of 2023 Corresponding Authors



The authors of TBCR come from diverse countries. In 2023, there were **33** corresponding authors coming from **9** different countries in TBCR, most of whom come from China, USA and Brazil, et al.

Note: Data were collected from January 1, 2023 to December 29, 2023

7. Website Visits in 2023




■ Others (including Japan, Austria, Italy, Canada, Singapore, Korea, Greece, Australia, Netherlands, Brazil, etc.)

Country	Visits
China	16,604
USA	13,390
India	3,428
UK	1,355
Japan	1,229
Netherlands	1,018
Italy	1,009
Other	11,532

All together **49,725** visitors between Jan. 2023 and Dec. 2023. Readers who visited TBCR website in this period were from diverse countries, with the majority from China, followed by USA, India, UK, Japan, etc.

Note: Data were collected from January 1, 2023 to December 29, 2023.

8. Pageviews in 2023



The pageviews of TBCR between Jan. 2023 and Dec. 2023 have increased, and the traffic reached **81,624** in total, and the average number of Pageviews per month reached **6,802**

Note: Data were collected from January 1, 2023 to December 29, 2023.

9. Most Viewed Articles Published in TBCR



Original Article:

[Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy](#)



Editorial Commentary:

[Advances of HER2 testing for women with breast cancer](#)



Review Article:

[Prospect of neoadjuvant/adjvant immunotherapy in early-stage triple-negative breast cancer](#)



Review Article:

[Breast cancer gene expression signatures: development and clinical significance—a narrative review](#)

10. Reviewer of the Month (2023)

In 2023, many TBCR reviewers make outstanding contributions to the peer-review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely helped the authors enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Nobuyuki Takahashi



supposed to be experts and have knowl
review without any biases.

Dr. Nobuyuki Takahashi is a clinical fellow in the Department of Medical Oncology at the National Cancer Center Hospital East, Kashiwa, Japan. His research area is clinical and translational research in neuroendocrine



The fields of Hematology and Oncology are excellent for patients, but it can be hard to find your data (or data you find important) and scientists. On the receiving end, it's often results, which I otherwise may have n

Dr. James M Martin is a breast cancer-focused medical oncologist at University Hospitals/Seidman Cancer Center and an Associate Professor at Case Western Reserve University (CWRU) School of Medicine. He is focused on medical education, healthcare disparities (including LGBTQ+ health), and estrogen receptor positive



on its originality and merit, one can minimize bias during review.

"Peer review can be tough and time-consuming, particularly for the ones who have clinical responsibilities and are not devoted completely to research work. However, achieving a review task is most definitely rewarding, and your contribution is certainly valuable to the scientific community that you are an integral part of. To the reviewers out there, I say: you people are the real MVPs!" says Dr. Gharib.

Dr. Khalil El Gharib is currently an Internal Medicine resident at Staten Island University Hospital in New York City. His research pathway started in oncology, where he contributed to the field through editorials, perspective letters, and other side papers initially, and then his scholarly activities included comprehensive reviews and original research papers. While his fellowship interests shifted into Pulmonary and Critical Care Medicine, he is proud of the physician-scientist persona that the field of oncology has shaped in him, and his future focuses will majorly intersect these two domains, i.e., research in lung cancer and in the challenges that the management of critically ill cancer patients in general imposes. Connect with Dr. Gharib on X @KhalilElGharib1.

Peer review guarantees the credibility and reliability of scientific research, seeking improvement in the quality of prepared manuscripts and prompting the publication of ethical, nonfraudulent scientific papers. Dr. Gharib believes that peer review plays a crucial role in disseminating truthful knowledge and in building trust within the science community.

Biases are unavoidable in peer review. In Dr. Gharib's opinion, one should be conscious of their own biases and preconceptions, as they potentially influence evaluation during peer review. However, through strict adherence to the journal's guidelines, opting to blind authors' and institutions' names, and evaluating the presented work based

11. Interviews with Outstanding Authors (2023)

In 2023, many TBCR authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulated a lot of discussions and new insights among their peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspectives and insightful views as authors.

Outstanding Author

Virginia Kaklamani



Dr. Kaklamani is Professor of Medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center in San Antonio, USA, and is the Leader of the Breast Cancer Program at the Mays Cancer Center. She completed her medical training with honors at the University of Athens and her residency in Internal Medicine at Newton-Wellesley Hospital in Boston, MA. She completed her fellowship in hematology/oncology at Northwestern University. She also received a Master of Science in Clinical Investigation from Northwestern University. She was the Head of the Translational Breast Cancer Program at Northwestern University and the co-director of the cancer genetics program at the same institution. She has also served as the Associate Director for Clinical Research at UT Health San Antonio. Her research interests include designing clinical trials with targeted agents. She has also identified several genetic mutations that link obesity and breast cancer. Connect with Dr. Kaklamani on X (Twitter).

From Dr. Kaklamani's perspective, science is all about exchanging ideas. Listening to others and critically evaluating their work make better scientists. To her, exchanging of ideas cannot happen without academic writing. In the process of academic writing, she thinks it is impossible to avoid bias. She explains, *"We all have innate biases which come from our own interpretation of data, but while these biases solidify our opinions, we need to listen to an opposing point of view with an open mind. The truth lies typically between two extremes."*

Dr. Kaklamani points out, when writing a scientific piece, it is authors' task to present the data in its entirety and provide all possible interpretations. She elaborates, *"If what we are writing is an opinion piece, then our personal interpretation is important; but we need to state this clearly. We should also provide the readers with other possible interpretations so that we can give them the opportunity to shape their own opinion."*


12. Cover Image Display



Vol 4(January 2023)



Vol 4 (April 2023)



Vol 4 (July 2023)



Vol 4 (October 2023)

In TBCR, different cover images are designed to highlight the featured article in each issue.

Note: Data were collected from January 1, 2023 to December 29, 2023

13. Introduction to the Publisher AME

Meet our Publisher

AME Publishing Company

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world

- **60+ peer-reviewed journals**
 - **19 indexed in SCIE/ESCI**
 - **20 indexed in PubMed**

- **200+ Medical Books**
 - **80+ Medical Books in English**
 - **120+ Medical Books in Chinese**
 - **150+ Electronic Editions**